The group demonstrated that dual AAV–mediated delivery of CRISPR-Cas9 and an Rpe65 donor sequence can lead to the correction of a disease-causing mutation in Rpe65 and an improvement in retinal function in a mouse model of LCA (Jo et al., 2019). The gene discussed is RPE65; the disease is Leber congenital amaurosis.